ActiveAtlas Opportunity Score 65/100
NCI SBIR Innovative Concept Award — 75N98026R00109
NCI Phase I SBIR contract offering $300,000 for high-risk, high-reward technologies in pediatric and rare cancers. Proposals are due September 21, 2026 at 5:00 PM ET. N9+ fit is conditional on a defensible cancer-specific R&D objective.
Funding$300,000 Phase I contract award.
DeadlineSeptember 21, 2026 at 5:00 PM Eastern Time.
Last verifiedSeptember 10, 2026
Required next actionRun a rapid cancer-specific technical screen before any direct pursuit. Advance only if N9+ or another Dr. Miltie capability can support a genuinely innovative pediatric- or rare-cancer research, detection, treatment, or care objective and all SBIR contract eligibility, registration, personnel, and submission requirements can be satisfied.
Broad Eligibility
Small-business contract opportunity. Applicants must satisfy the NCI SBIR solicitation's small-business, registration, technical, personnel, and submission requirements and use the Contract Proposal Submission system.
Atlas Analysis
Atlas Opportunity Score 65/100. Provisional N9+ Fit Score 65/100 and highly conditional. Do not force-fit generic remote examination or telehealth. A TRUE direct pursuit requires a strong pediatric- or rare-cancer-specific innovation thesis and legitimate evidence that Dr. Miltie can meet every mandatory solicitation requirement.
The National Cancer Institute is accepting proposals for its SBIR Innovative Concept Award, notice 75N98026R00109, a Phase I contract opportunity for highly innovative technologies intended to improve research, prevention, detection, or care in pediatric and rare cancers.
Proposal deadline: September 21, 2026 at 5:00 PM Eastern Time. The award provides $300,000 for Phase I R&D. Proposals must be submitted through the Contract Proposal Submission system.
Atlas fit: Conditional. N9+ would require a defensible pediatric- or rare-cancer-specific scientific and technical R&D objective; general telehealth, remote examination, or monitoring without a direct cancer research or care innovation is not sufficient. Preliminary data is not required, and the program emphasizes high-risk/high-reward innovation.
This is a small-business contract opportunity. Dr. Miltie should not advance a direct response unless its small-business eligibility, registrations, cancer-specific technical premise, personnel qualifications, and all solicitation requirements can be documented legitimately.
From Funding to Implementation · Pediatric Access Solution
Translate pediatric funding into more complete virtual encounters.
Dr. Miltie N9+ can help pediatric programs bring clinician-directed examination closer to children and caregivers, including families facing distance, mobility or sensory barriers.
Source verificationOfficial government source · sbir.cancer.govAtlas last verified this record September 10, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
